A randomised controlled trial of early intervention with oral favipiravir in patients hospitalised with COVID-19 (PIONEER Trial)
C. Orton (London, United Kingdom), P. Shah (London, United Kingdom), B. Grinsztejn (Rio de Janeiro, Brazil), G. Donaldson (London, United Kingdom), B. Crabtree Ramírez (Mexico City, Mexico), J. Tonkin (London, United Kingdom), B. Santos (Porto Alegre, Brazil), S. Cardoso (Rio de Janeiro, Brazil), A. Ritchie (London, United Kingdom), F. Conway (London, United Kingdom), M. Riberio (Rio de Janeiro, Brazil), D. Wiseman (London, United Kingdom), A. Tana (London, United Kingdom), B. Vijayakumar (London, United Kingdom), C. Caneja (London, United Kingdom), C. Leaper (London, United Kingdom), B. Mann (London, United Kingdom), A. Samson (Hull, United Kingdom), P. Bhavsar (London, United Kingdom), M. Boffito (London, United Kingdom), M. Johnson (London, United Kingdom), A. Pozniak (London, United Kingdom), M. Pelly (London, United Kingdom)
Source: International Congress 2022 – ALERT 3: COVID and interstitial lung diseases??
Session: ALERT 3: COVID and interstitial lung diseases??
Session type: Clinical trials session
Number: 2882
  
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Orton (London, United Kingdom), P. Shah (London, United Kingdom), B. Grinsztejn (Rio de Janeiro, Brazil), G. Donaldson (London, United Kingdom), B. Crabtree Ramírez (Mexico City, Mexico), J. Tonkin (London, United Kingdom), B. Santos (Porto Alegre, Brazil), S. Cardoso (Rio de Janeiro, Brazil), A. Ritchie (London, United Kingdom), F. Conway (London, United Kingdom), M. Riberio (Rio de Janeiro, Brazil), D. Wiseman (London, United Kingdom), A. Tana (London, United Kingdom), B. Vijayakumar (London, United Kingdom), C. Caneja (London, United Kingdom), C. Leaper (London, United Kingdom), B. Mann (London, United Kingdom), A. Samson (Hull, United Kingdom), P. Bhavsar (London, United Kingdom), M. Boffito (London, United Kingdom), M. Johnson (London, United Kingdom), A. Pozniak (London, United Kingdom), M. Pelly (London, United Kingdom). A randomised controlled trial of early intervention with oral favipiravir in patients hospitalised with COVID-19 (PIONEER Trial). 2882
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|